Supplemental Online Content

Kim EJ, Mangold AR, DeSimone JA, et al. Efficacy and safety of topical hypericin photodynamic therapy for early-stage cutaneous T-cell lymphoma (mycosis fungoides): the FLASH phase 3 randomized clinical trial. *JAMA Dermatol*. Published online July 20, 2022. doi:10.1001/jamadermatol.2022.2749

eFigure 1. CONSORT Diagram

eFigure 2. Visible-Light Skin Penetration

This supplemental material has been provided by the authors to give readers additional information about their work.

eFigure 1) FLASH STUDY: CONSORT Diagram

Enrollment

Randomized (n=169)

Allocation

Hypericin (n = 118)

Cycle 1 (n = 116, 98.3%)

Cycle 2 (n = 110, 93.2%)

Cycle 3* (n = 78, 66.1%)

Did not receive intervention (n = 2)

Placebo (n = 51)

Cycle 1 (n = 50, 98.0%)

Cycle 2 (n = 45, 88.2%)

Cycle 3* (n = 32, 62.7%)

Did not receive intervention (n = 1)

Withdrawal

Adverse events (n = 2, 1.7%)
Voluntary (n = 13, 11.2%)
Lost to follow up (n = 11, 9.5%)
Investigator judgment (n = 1, 0.9%)
Pregnancy (n = 1, 0.9%)
Noncompliance (n = 2, 1.7%)
% relative to enrolled in Cycle 1

Adverse events (n = 0)
Voluntary (n = 9, 18%)
Lost to follow up (n = 5, 10%)
Investigator judgment (n = 1, 2%)
Pregnancy (n = 0)
Noncompliance (n = 0)
% relative to enrolled in Cycle 1

Analysis

Analysed (n= 110)
Excluded from analysis (n=2):

· Did not receive study drug

Analysed (n= 50)
Excluded from analysis (n=1):

· Did not receive study drug

eFigure 2) Light Penetration in Skin as a Function of Wavelength

